SAKhARNYY DIABET 2 TIPA I NEALKOGOL'NAYa ZhIROVAYa BOLEZN' PEChENI: PRAKTIChESKIE REKOMENDATsII DLYa ENDOKRINOLOGOV


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

In clinical practice, type 2 diabetes mellitus (DM2) is often associated with non-alcoholic fatty liver disease (NAFLD), which includes several morphological forms and develops in patients without alcohol abuse. The combination of DM2 and NAFLD is associated not only with a high risk of liver cirrhosis and hepatocellular carcinoma in these patients. The presence of NAFLD in DM2 patients is also a predictor of high cardiovascular risk and increased mortality. Despite the findings on the progressive nature of NAFLD in DM2 patients, treatment of NAFLD in DM2 patients remains unclear.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Ametov

Әдебиет тізімі

  1. Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113-19.
  2. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7(8): 456-65.
  3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142 (7):1592-609.
  4. Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
  5. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hithertounnamed disease. Mayo Clin Proc 1980;55:434-38.
  6. de Marco R. et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-61.
  7. Targher G. et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-46.
  8. Schuppan D, Gorrell MD, Klein T, et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010;30(6):795-808.
  9. Liagnpunsakul S, Chalasani N. What do we recommend our patients with NAFLD about alcohol consumption? Am J Gastroenterol 2012l;107(7):976-78.
  10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol 2003;98:960-7.
  11. Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol 2007;102: 399-408.
  12. Machado M., Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-6.
  13. Marchesini G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
  14. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
  15. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Ann 1989;24:275-302.
  16. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-65.
  17. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006;29:1845-50.
  18. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285,E906-E16.
  19. Banerji M.A, et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995;19:846-50.
  20. Targher G, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-9.
  21. Targher G, et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005;22:1354-58.
  22. Targher G, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006;29:55-60.
  23. Lautam ki R, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006;291:E282-E90.
  24. Day CP, James OF. Steatohepatitis: a tale of two “hits"? Gastroenterology 1998;114:842-45.
  25. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
  26. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52.
  27. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steato-hepatitis. Hepatology 2002;35:898-904.
  28. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1705-25.
  29. Fracanzani AL, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-98.
  30. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis 2012;16(3):567-85.
  31. Palmentieri B. et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485-9.
  32. Mottin CC, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635-7.
  33. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
  34. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
  35. Ratziu V, Giral P, Charlotte F, et al. Liver fibro sis in overweight patients. Gastroenterology 2000;118(6):1117-23.
  36. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1): 91-100.
  37. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84(5):1513-17.
  38. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54.
  39. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-47.
  40. Miyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008;28(4):519-24.
  41. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44(1): 27-33.
  42. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepati-tis: a multicenter validation study. Hepatology 2009;50(4):1072-78.
  43. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11(2):255-29.
  44. Santos VN, Leite-Mor MM, Kondo M, et al. Serum laminin, type IV collagen and hyaluro-nan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005;38(5): 747-53.
  45. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.
  46. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47(2):455-60.
  47. Nobili V, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric nonalcoholic fatty liver disease. Gastroenterology 2009;136(1):160-57.
  48. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127(6):1704-13.
  49. Tamura, Y. et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191-96.
  50. Sjstr m, L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
  51. Chavez-Tapia NC, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD007340. doi: 10.1002/14651858. CD007340. pub2, 2010.
  52. Musso G, Gambino R, Cassader M, et al. A metaanalysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
  53. Selvin E, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-80.
  54. Aithal GP, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84.
  55. Belfort R, et al. A placebo-controlled trial of pio-glitazone in subjects with nonalcoholic steato-hepatitis. N Engl J Med 2006;355:2297-307.
  56. Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
  57. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
  58. Lincoff A, Wolski K, Nicholls S, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007;298:1180-88.
  59. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
  60. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis JAMA 2007;297(8):842-57. Review. Erratum in: JAMA 2008;299(7):765-66.
  61. Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011;306:1549-56.
  62. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287-92.
  63. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5.
  64. Chalasani N. Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005;41:690-5.
  65. Lewis JH, Mortensen ME, Zweig S, et al. Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double blind, placebocontrolled, multicenter trial. Hepatology 2007;46(5):1453-63.
  66. Horlander JC, Kwo PY, Cummings OW, et al. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120(Suppl.):2767.
  67. Gomer-Dominguez E, Gisbert JP, Moreno-Monteagudo A, et al. A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-47.
  68. Antonopoulos S, Mikros S, Mylonopoulos M, et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184: 233-34.
  69. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St. Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2011;106:71-7.
  70. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-й выпуск// Сахарный диабет 2011. № 3 (приложение).
  71. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad Med 2010;122:16-27.
  72. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50(4):253-65.
  73. Инструкция по медицинскому применению лекарственного препарата Онглиза (таблетки, покрытые оболочкой, 2,5 мг, 5 мг). Регистрационное удостоверение ЛСР 08697/10 (изменение №1) от 30.03.2012.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>